kallikrein related peptidase 7Genealiases: PRSS6 · SCCE · hK7
Q-omics provides the consensus-scored KLK7 profile across patient tissues and cancer cell-line models. KLK7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, KLK7 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KLK7 RNA expression shows 15,628 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where KLK7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK7 survival associations across molecular data types. KLK7 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK7 RNA expression–survival associations across cancer types. High KLK7 expression shows unfavorable associations in BLCA, KIRP, UCEC and PAAD, but favorable associations in THCA and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for KLK7 RNA expression.
This table summarizes KLK7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KLK7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK7 shows lower tumor expression in KIRC, KIRP, BRCA and KICH and higher tumor expression in THCA and COAD. The KIRC box plot shows higher KLK7 RNA expression in normal versus tumor tissue (log2 FC = −3.580, t-test p < 0.001).
This table shows molecular features associated with KLK7 in patient tissues and cancer cell lines. In patient samples, KLK7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and OVARY.
